Nanowired cardiac organoids and the electrode-tissue interface

What the work claims

Two kinds of claim are bundled here, and they deserve different weight. The first is a published primary result. Tan and colleagues (Mei lab, Clemson, with collaborators at the University of Chicago and the Medical University of South Carolina) showed that human cardiac organoids built with electrically conductive silicon nanowires (e-SiNWs) outperformed identical unwired organoids on electrical pacing and on every functional endpoint measured after transplantation into ischemia-reperfusion injured rat hearts¹. The grant record states the headline number directly: nanowired organoids achieved roughly 69 percent fractional shortening recovery, against comparison studies that had injected a tenfold greater number of dissociated cardiomyocytes².

The second is a program of proposed work in the active R01 that funds the follow-up: optimizing nanowire surface roughness, preconditioning organoids with a PHD2 inhibitor to improve engraftment, and validating the construct in a porcine model. Those are aims, not results. This article leads with the published mechanism and treats the grant as context for where the effort and money are going.

How it works

The e-SiNWs are n-type, about 100 nm in diameter and about 10 micrometers long, doped to a conductivity of 150 to 500 microSiemens per micrometer. For scale, the surrounding cell culture medium sits near 1.75 and myocardium near 0.1 microSiemens per micrometer in the same units, so the nanowires are three to four orders of magnitude more conductive than the tissue they are mixed into¹. Roughly a thousand nanowires accompany roughly a thousand cardiomyocytes in each starting spheroid.

The control experiment that isolates the mechanism is the load-bearing one. Undoped silicon nanowires, with a conductivity of 0.001 to 0.1 microSiemens per micrometer, produced no significant improvement in contractility; only the doped, highly conductive wires did. The benefit tracks conductivity itself, not nanowire geometry, surface chemistry in general, or a cellular response to a foreign body¹.

Functionally, in vitro, nanowired organoids kept pace with external field stimulation at higher rates than unwired organoids and showed greater fractional area change when paced up to 1.5 Hz, using 12 V per cm, 5 ms pulses across 0.5 to 2.5 Hz. After transplantation, nanowired grafts expressed more connexin-43 at day 28 (roughly 5 micrometer z-line width versus 3.5 for unwired grafts), indicating better-preserved electrical coupling inside the graft, and showed greater graft vascularization¹. Electrocardiograms showed no arrhythmias after direct myocardial injection of 5 million nanowires, and nanowired spheroids formed connexin-43 and N-cadherin junctions with healthy host myocardium in the biocompatibility arm of the study.

Where a skeptic should push

The single most load-bearing assumption is that conductivity, proven causal for the in vitro pacing and contractility benefits, is also what drives the in vivo functional recovery. That is asserted, not demonstrated. The authors themselves flag the gap: in the infarcted hearts they did not observe connexin-43 coupling between graft and host, and they call for gene-expression studies to understand how the repair actually happens. A nanowire scaffold could be improving survival, vascularization, or maturation by mechanisms that have nothing to do with electrical shunting¹.

Second, the impressive headline numbers are cross-study comparisons, not head-to-head trials. The roughly 69 percent fractional shortening recovery is normalized to an injury that cost about 23 percent of fractional shortening in this study's own cohort, and the comparator studies used the same injury model but different cell preparations and historical baselines. The in vivo arm had n = 5 to 6 animals, a sample size the authors themselves name as a limitation. Small-n rodent efficacy results in cardiac cell therapy have a well-documented habit of shrinking in larger trials¹.

Third, everything above describes field stimulation of bulk tissue with plate electrodes, not microelectrode array recording or stimulation. No MEA appears in this work. Extending its conclusions to array hardware is the analysis this article performs, and it should be read as informed extrapolation, not as anything the authors claimed.

What nanowired tissue means for array hardware

The non-obvious implication is that the tissue-electrode interface problem is being attacked from the tissue side, and the same tool that fixes stimulation capture can sabotage recording. A 3D organoid sitting on a planar MEA is electrically invisible in its interior: extracellular current from deep cells spreads through poorly conductive tissue, and the recorded field potential is dominated by the surface layer. A conductive nanoscaffold dispersed through the organoid changes the volume-conduction geometry. That is the opportunity. If interior cells are electrically wired to the surface, high-density arrays could see activity that is currently out of reach, and stimulation current needed to pace the construct could drop sharply, because the field no longer has to fight its way through a resistive interior. Lower stimulation voltage means lower charge injection at the electrode per pulse, less electrolysis and pH drift at the interface, and slower electrode wear. For chronic organoid experiments where stimulation electrodes degrade session over session, a tissue-side conductivity boost is a legitimate lever.

The threat is the mirror image, and it is physics, not engineering risk. The extracellular voltage an MEA records is generated precisely because transmembrane current must flow through a resistive extracellular space. Short out that resistance with a scaffold several thousand times more conductive than tissue and the local extracellular field collapses for the same membrane activity. There is a real possibility that a nanowire loading optimized for pacing capture quietly reduces the amplitude of the very field potentials the acquisition chain is trying to measure. Whether the trade is favorable depends entirely on geometry: where the wires sit relative to the electrodes, how much extracellular path remains unshunted, and whether the signal gain from newly visible interior cells outweighs the amplitude loss from reduced extracellular resistance. Nobody has run that experiment on an MEA, and it is the first experiment a hardware group should run before adopting these constructs.

There is also a subtler instrumentation consequence. A conductive scaffold makes the tissue an active part of the electrode system, so the array's calibration drifts with the tissue state. Nanowire density, dispersion, and degradation are biological process variables, not fixed device parameters; an acquisition chain calibrated against a plain organoid cannot assume the same transfer function for a nanowired one. Treating engineered tissue as a component with a datasheet you do not control is exactly the kind of assumption that produces unreproducible electrophysiology.

The bottom line

Established: doped silicon nanowires are biocompatible, their conductivity (not their presence) causally improves paced contractility in vitro, and nanowired cardiac organoids improved functional recovery in a small rat study. Asserted but unproven: that electrical conductivity is the mechanism of the in vivo benefit, that nanowire surface roughness can be engineered for further gains, and that the construct survives translation to porcine hearts. For microelectrode array work, the constructive hypothesis is testable this quarter: wire and unwired organoids on identical high-density arrays, measure pacing threshold, field potential amplitude, and signal origin depth side by side. If the nanowired constructs record as well as they pace, the tissue side of the interface becomes a genuine design space. If the recordings flatten, the same conductivity that helps stimulation has eaten the signal.